- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
July 1st, 2009
Although predicted by many to be the future of biotech and pharma R&D, investment in nanotechnology has been unexpectedly low so far, with few companies willing to take that financial risk. A focus group has been established in the UK with major industry stakeholders to assess how companies can take on the risk of an unproven technology in a highly regulated industry. The author believes, however, that the successful early adopters of nanotech will reap the rewards.
Nanotech has much to offer the pharma industry; if it follows previous technology examples, such as biotech, the successful early adopters will reap the rewards. However, there are still a number of hurdles to overcome, such as a clear regulatory pathway and a demonstration of value above and beyond current technologies, before it can become mainstream. There are significant efforts by industry and governments to help nanotech to jump the technology adoption gap quickly and ensure it can assist in developing the next generation of products, which are needed to solve significant unmet medical needs faced by patients and healthcare professionals.
|Related News Press|
News and information
Healthcare Nanotechnology (Nanomedicine) Market Size To 2020 June 5th, 2015
Newly-Developed Biosensor in Iran Detects Cocaine Addiction June 23rd, 2015
Researchers first to show that Saharan silver ants can control electromagnetic waves over an extremely broad range of the electromagnetic spectrum—findings may lead to biologically inspired coatings for passive radiative cooling of objects June 19th, 2015
Cellulose from wood can be printed in 3-D June 17th, 2015